Reye's syndrome (RS) is a rare but severe neurological disorder complicated by hepatic dysfunction and predominantly affecting children. It was first described as a clinicopathological entity by Reye, an Australian pathologist, in 19631 .
A brief review of the clinical and epidemiological features is pertinent to an understanding of the issues of studying the risk factors for developing RS.
Clinical and epidemiological features of RS In the typical case a previously healthy child acquires a common viral infection which is apparently taking a normal course when there is a sudden onset of profuse persistent effortless vomiting, accompanied or shortly followed by alteration in conscious level. Liver involvement is indicated by grossly elevated levels of serum aspartate and alanine transaminases and the blood ammonia level is also usually raised. There are histological and ultrastructural changes in the liver. These include diffuse panlobular microvesicular fatty infiltration and swollen, disrupted mitochondria.
The Centers for Disease Control (CDC) have maintained national surveillance ofRS since 1974 The epidemiological evidence is also controversial. It is hard to explain why an aspirin association would explain an excess occurrence ofRS in rural areas.
The early reports of an RS-aspirin association are difficult to interpret because they are uncontrolled. The case-control design is appropriate for studying risk factors for rare diseases but is inherently subject to several forms of biases, and it was the demonstration of those in the first 3 studies, following release of the raw data, that led to the call for a new study and to the decision reversals outlined above. The criticisms have been reviewed in detail9'25'26 but can be summarized as follows: firstly, selection biasdid the cases really have RS? Was it certain, for example, that they did not include patients with aspirin toxicity? Were the controls equally at risk of developing RS in respect of all other parameters except aspirin usage (they were not matched for type, severity and viral cause of the prodrome).
Secondly, recall bias: memory is worse for controls than cases because the event is less significant and these interviews took place after a longer interval than those for cases.
Third, data collection bias: the interviewers were aware of the research hypothesis and of the designation of their subjects (case or control).
Fourth, categorization bias: product identification was more accurate for controls than for cases because the former were interviewed at home.
Fifth, protopathic bias: exposure to the risk factor should precede onset of disease. The problem is that the clinical marker for onset of RS is unknown. It is normally taken to be the vomiting but it is always possible that it begins earlier. It was only possible to assess this in one part of one of the studies because of the methods ofdata collection.
The methodology of the fourth (pilot phase) casecontrol study attempted to overcome these and other criticisms, but it still retained the potential for serious biases27. The most important ofthese relate to the widespread knowledge of the association which means, firstly, that there could have been preferential diagnosis and/or reporting of patients with the diagnostic criteria plus a history of aspirin ingestion. Secondly, parents may consciously (with litigation in mind) or unconsciously have reported aspirin use once they knew the diagnosis.
Conclusion
If the criteria for judging causality are applied to the evidence outlined above for and against an RS-aspirin association, an ambiguous picture emerges: in the case-control studies the temporal relationship appears satisfactory at first but there are problems in defining the onset of RS. On the wider time scale, however, perhaps the most convincing piece of evidence in favour of the relationship is the natural 'experiment' illustrated by the long-term trends in the annual incidence of RS in the USA.
The steady fall since 1980, which accelerated in 19855, is temporally related to publicity about the association and has occurred in cases associated with both varicella (which has a steady annual incidence) and influenza (whose type and activity fluctuates annually). Furthermore, there is evidence that this decline has been paralleled by a decline in aspirin usage among children28'29.
The association has been consistently shown in the American epidemiologial studies although the only other published study, from Japan, did not show such an association (but the methodology was not described) 30 . Further evidence of consistency of association was provided by finding an increased risk ofRS among children on long-term salicylate therapy for connective dissue disorders3 -33.
The association in the USA studies was strong but those studies have been criticized for serious biases which, on reanalysis, reduced the strength; the association is not specific -there is experimental and epidemiological evidence linking other exogenous agents to RS. The association appears to be biologically plausible but the experimental evidence in support of this is conflicting.
In summary, a question mark has been hung over the safety of aspirin when given to children with common viral infections. The evidence to date is conflicting and each piece, taken on its own, might not be convincing. Nevertheless, the accumulated weight of the evidence, together with the serious nature of RS and the availability ofalternative effective remedies, has led to the recent recommendations in Britain34 that aspirin should not be given to children under 12 years of age unless specifically indicated for childhood rheumatic conditions.
